International Lung Cancer Summit

🚨 Check our Top 10 #LungCancer abstracts for ELCC 2026! We've hand-picked the must-see sessions with times & presenters. 🗓️ Stay on track in Copenhagen and simply import these directly to your calendar by clicking this link: lungsummit.org/elcc2026.ics Which lung abstracts are your favorites at ELCC26 #LCSM @IASLC @myESMO

Managing dermatologic toxicities may look easy in trial settings, but not in the real world. At ILCS 2025, @tnewsomdavis reminded the audience that most hospitals don’t have instant access to dermatology teams. His message: treatments must be practical and manageable for the many, not just for specialized centers. Watch the discussion ⬇️ lungsummit.org/targeted-thera…

With the #ELCC26, organized by @myESMO and @IASLC, just around the corner, we are happy that our foundation will be highly visible throughout the congress with 2 presentations, 4 posters and session on "T-cell engagers: A new class of drugs", running Friday, 27 March.

Rechallenging with immunotherapy in 2L NSCLC remains difficult. As @MdCurioni explained, most phase 3 trials combining ICIs with VEGF or TKI inhibitors, including PRAGMATICA-LUNG and CONTACT-01, failed to improve OS. Only nintedanib + docetaxel and ramucirumab + docetaxel have shown encouraging signals so far (~35%). Watch the full talk here 👇 🔗 lungsummit.org/metastatic-nsc…

So true. Not long ago small cell lung cancer meant platinum etoposide followed by hospice. #SCLC

🆕 Article in press: MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies. @mihaela_aldea 👉 annalsofoncology.org/article/S0923-…

With multiple MTA-cooperative #PRMT5i now in phase 1/2 trials, MTAP testing should be considered in oncogene-driven #NSCLC. More than 1 in 3 patients with ALK+ disease may harbor MTAP loss. Next step: TKI + PRMT5i combination trials. @DanaFarber @GustaveRoussy @AlkRos1France @ALKPositiveinc

🫁 A potential new vulnerability in oncogene-driven NSCLC. MTAP loss - a metabolic alteration present in ~10-15% of cancers - appears particularly frequent in EGFR, ALK and RET driven lung cancers. A new Annals of Oncology study explores its biological and therapeutic implications. 🧪 Key findings 🔬 MTAP loss prevalence • EGFR-mutant NSCLC • ALK-rearranged NSCLC • RET-rearranged NSCLC ⚠️ Clinical impact MTAP loss did NOT worsen outcomes with frontline TKIs like osimertinib or alectinib. 💊 Therapeutic opportunity MTAP-deleted tumors showed strong sensitivity to PRMT5 inhibition. The MTA-cooperative PRMT5 inhibitor BMS-986504 demonstrated: ✅ Antitumor activity in MTAP-deleted models ✅ Activity across EGFR and ALK driven tumors ✅ Additive / synergistic effects when combined with targeted therapy 🎯 Why this matters MTAP deletion may define a new combinatorial strategy in oncogene-driven lung cancer: TKI + PRMT5 inhibition A potential next wave of precision thoracic oncology. 🔖 Worth watching as PRMT5 inhibitor trials mature. 📖 Full paper in comment ⬇️ #OncoTwitter #LungCancer #NSCLC #PrecisionOncology @OncoAlert @ASCO @myESMO

Induced proximity-based therapeutic modalities rdcu.be/e8CrR nature.com/articles/s4157… This Review in the March issue covers the range of therapeutic modalties that act by inducing interactions between biomolecules, including molecular glues and bifunctional molecules

Longer follow up from LUMINOSITY study @JTOonline: telisotuzumab vedotin (cMET ADC) in cMET+, EGFR wild type, non-squamous NSCLC had RR 29.2% with DOR 7.2m. In cMET high, RR 34.5% and in cMET int, RR 23.8%. Neuropathy seen in 31% (7% G3+). jtocrr.org/article/S2666-…

Ph I/II trial of lurbinectedin + irinotecan in relapsed SCLC @JTOonline: - 47pts - ORR 61.9%, mPFS 7.2m, mOS 12.3m - based on in vitro/in vivo work showing synergy by DNA damage & apoptosis @OncoAlert @SclcSMASHERS #LCSM jto.org/article/S1556-…

More disappointment with anti-TIGIT therapy. Results from phase III KEYVIBE-010 study of adjuvant vibostolimab coformulated with pembrolizumab versus pembro alone in resected melanoma fails to improve recurrence free survival (HR 1.25) and adds toxicity. thelancet.com/journals/lanon…

What's the role of lurbinectedin in frontline SCLC in the US? At our Year in Review @peters_solange challenged @charlesrudin on his approach to the IMforte data. While acknowledging the survival advantage he highlighted a real world dilemma, as some patients may need a break from cytotoxic therapy after induction or lack the marrow reserve to continue immediately. Watch the full debate together with @MartinReck2 ➡️ lungsummit.org/all-sessions/

Phase I ARTEMIS-001 trial of the B7-H3 ADC HS-20093 (GSK5764227) now @Cancer_Cell. In SCLC, RR 52%, DOR 7.1m with greater RR if topoisomerase I inhibitor naive vs treated (60% vs 17%), but no difference by platinum sensitivity. B7-H3 IHC not predictive. cell.com/cancer-cell/fu…

Results from CHIO3 (CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer), AFT-46 study online. Phase II study of durvalumab + neoadjuvant chemo showed N2 nodal clearance rate of 73%, pCR 30%. lungcancerjournal.info/article/S0169-…

Not long ago small cell lung cancer meant platinum etoposide followed by hospice. Today we have immune checkpoint blockade and tarlatamab but what comes next? @charlesrudin shared his outlook at our roundtable suggesting that novel agents like radio conjugates and CAR T cells might soon crowd the treatment sequence. Watch the full discussion with @peters_solange and @MartinReck2 to see where the field is heading ➡️ lungsummit.org/all-sessions/

ctDNA could redefine how we personalize IO in LS-SCLC. In his ILCS2025 talk, @RManochakian highlighted how combining ctDNA with radiologic markers may identify who truly benefits from consolidation immunotherapy after chemoradiation, a key step toward precision in SCLC. Watch the full talk here ⬇️ lungsummit.org/sclc/

Can induction chemo-immunotherapy followed by cCRT and maintenance IO reshape outcomes in unresectable stage III NSCLC? At ILCS 2025, @AndrearicFili highlighted phase II data from @MARIANOPROVENCI’s APOLO trial and Dr. William’s Latin American study, both showing ~70% 12-month PFS with induction CT-IO followed by cCRT and IO maintenance. The InTRist trial added toripalimab, reaching 85% 1-year PFS. Watch the full talk ⬇️ lungsummit.org/metastatic-nsc…

T cell engagers are transforming small cell lung cancer but why is NSCLC lagging behind? During our Year in Review roundtable @MartinReck2 and @peters_solange debated the future of this technology with @charlesrudin. They explored whether the unique immune environment of SCLC is the key to their success and what this means for other immunotherapy strategies moving forward. Watch the roundtable here ⬇️ lungsummit.org/all-sessions/

What lies beyond the current wave of bispecifics and ADCs in lung cancer? At our Year in Review @charlesrudin and @peters_solange pointed to cell based therapies as the next major frontier. Although efficacy in solid tumors remains a hurdle, innovations like CAR T cells might change the long term outlook. Are our clinics ready for this shift? Watch the full roundtable with @MartinReck2 ➡️ lungsummit.org/all-sessions/